CVE:TLT Theralase Technologies (TLT) Stock Price, News & Analysis C$0.18 -0.01 (-5.41%) As of 11/20/2026 03:51 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Theralase Technologies Stock (CVE:TLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theralase Technologies alerts:Sign Up Key Stats Today's RangeC$0.17▼C$0.1850-Day RangeC$0.18▼C$0.2252-Week RangeC$0.15▼C$0.41Volume62,362 shsAverage Volume224,518 shsMarket CapitalizationC$54.33 millionP/E RatioN/ADividend Yield1,657.14%Price TargetN/AConsensus RatingN/A Company Overview Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada. Read More Receive TLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLT Stock News HeadlinesTheralase Provides Bladder Cancer Clinical Study UpdateOctober 26, 2026 | marketscreener.comMTheralase(R) to Present at ThinkEquity ConferenceOctober 9, 2026 | finance.yahoo.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 22 at 1:00 AM | Paradigm Press (Ad)Theralase Technologies Inc.: Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial StatementsSeptember 18, 2026 | finanznachrichten.deTheralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)September 15, 2026 | theglobeandmail.comCancer fighter Theralase aims to turn lab wins into human trialsSeptember 15, 2026 | msn.comTheralase Technologies Inc.: Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)September 15, 2026 | finanznachrichten.deTheralase Technologies Inc TLTSeptember 2, 2026 | morningstar.comMSee More Headlines TLT Stock Analysis - Frequently Asked Questions How have TLT shares performed this year? Theralase Technologies' stock was trading at C$0.17 at the beginning of 2026. Since then, TLT stock has increased by 6.1% and is now trading at C$0.18. How do I buy shares of Theralase Technologies? Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Theralase Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include Netflix (NFLX), NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Cresco Labs (CRLBF), Curaleaf (CURLF) and Aurora Cannabis (ACB). Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolCVE:TLT CIKN/A Webtheralase.com Phone+1-416-6995273FaxN/AEmployees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$4.49 million Net Margins-472.48% Pretax MarginN/A Return on Equity-130.04% Return on Assets-81.88% Debt Debt-to-Equity Ratio2.17 Current Ratio5.48 Quick Ratio3.40 Sales & Book Value Annual SalesC$802.46 thousand Price / Sales67.71 Cash FlowC$0.01 per share Price / Cash Flow30.45 Book ValueC$0.02 per share Price / Book7.26Miscellaneous Outstanding Shares310,483,000Free FloatN/AMarket CapC$54.33 million OptionableNot Optionable Beta-1.37 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (CVE:TLT) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theralase Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theralase Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.